Reference : Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness compari...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/70106
Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol.
English
Scholtissen, S. [> > > >]
Bruyère, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Neuprez, A. [> > > >]
Severens, J. L. [> > > >]
Herrero-Beaumont, G. [> > > >]
Rovati, L. [> > > >]
Hiligsmann, Mickaël mailto [Université de Liège - ULg > HEC-Ecole de gestion de l'ULg : UER > Economie industrielle >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
2010
International Journal of Clinical Practice
Blackwell Publishing
64
6
756-62
Yes (verified by ORBi)
International
1368-5031
1742-1241
Oxford
United Kingdom
[en] INTRODUCTION: The aim of this study was to explore the cost-effectiveness of glucosamine sulphate (GS) compared with paracetamol and placebo (PBO) in the treatment of knee osteoarthritis. For this purpose, a 6-month time horizon and a health care perspective was used. MATERIAL AND METHODS: The cost and effectiveness data were derived from Western Ontario and McMaster Universities Osteoarthritis Index data of the Glucosamine Unum In Die (once-a-day) Efficacy trial study by Herrero-Beaumont et al. Clinical effectiveness was converted into utility scores to allow for the computation of cost per quality-adjusted life year (QALY) For the three treatment arms Incremental Cost-Effectiveness Ratio were calculated and statistical uncertainty was explored using a bootstrap simulation. RESULTS: In terms of mean utility score at baseline, 3 and 6 months, no statistically significant difference was observed between the three groups. When considering the mean utility score changes from baseline to 3 and 6 months, no difference was observed in the first case but there was a statistically significant difference from baseline to 6 months with a p-value of 0.047. When comparing GS with paracetamol, the mean baseline incremental cost-effectiveness ratio (ICER) was dominant and the mean ICER after bootstrapping was -1376 euro/QALY indicating dominance (with 79% probability). When comparing GS with PBO, the mean baseline and after bootstrapping ICER were 3617.47 and 4285 euro/QALY, respectively. CONCLUSION: The results of the present cost-effectiveness analysis suggested that GS is a highly cost-effective therapy alternative compared with paracetamol and PBO to treat patients diagnosed with primary knee OA.
http://hdl.handle.net/2268/70106
10.1111/j.1742-1241.2010.02362.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Glucosamine sulphate in the treatment of knee osteoarthritis Cost-effectiveness comparison with paracetamol.pdfPublisher postprint254.48 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.